Sub-Q Bionics Announces Licensing Agreement to Advance Lymphedema Care

Contributed by: Business Wire

Logo

Tags

Health

Medical Devices

Other Health

General Health

Research

Science

Biotechnology

lymphatic drainage

More Like This

Sub-Q Bionics Closes $1.5M Pre-Seed Round to Advance Next-Generation Solution for Lymphedema Care

New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer's disease

New data from LEQEMBI® (lecanemab-irmb) phase 3 Clarity AD study and subcutaneous formulation presented at CTAD

BLA for subcutaneous formulation of Leqembi® accepted in China

Lindy Biosciences Enters Licensing and Collaboration Agreement With Novartis for Multi-target Drug Delivery Innovation

SIBIONICS and PharmaSens Explore New Horizons for Automated Insulin Delivery at EASD 2026

PR Newswire associated0

UroMems Receives Clearance from the FDA and the French ANSM for Initiating Landmark Pivotal Clinical Study of UroActive® Smart Implant to Treat Male Stress Urinary Incontinence

FDA accepts Biologics License Application for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US